COMMUNIQUÉS West-GlobeNewswire

Pulselight appoints Sir Jonathan Van-Tam as an Advisor
30/09/2025
Sir Jonathan Van-Tam joins Pulselight to support its mission to transform the UK health system by reducing waiting lists, driving efficiencies and improving patient outcomes LONDON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
30/09/2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 30 September 2025 at 9.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks
30/09/2025
Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in emergencies. The test helps clinicians quickly identify heart attack and rule out non-cardiac [...]
Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®
30/09/2025
Long-lasting antibody persistence was comparable in older (65+) and younger adults Long-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunya [...]
Valneva annonce un taux de séroréponse de 95% quatre ans après une vaccination avec une seule dose du vaccin contre le chikungunya IXCHIQ®
30/09/2025
Persistance des anticorps chez les adultes âgés de 65 ans et plus, comparable à celle des jeunes adultes La durabilité de la réponse immunitaire est un avantage compétitif clé pour un vaccin ciblant une maladie [...]
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
30/09/2025
Cash position of CHF 2.3 million at end of H1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced [...]
Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025
30/09/2025
Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 Schlieren (Zürich), Switzerland – September 30, 2025 – Kuros Biosciences (“Kuros” or the “Company”), a leader in innovative [...]
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
30/09/2025
Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its multi-target [...]
Artelo Biosciences Announces Proposed Underwritten Public Offering
30/09/2025
SOLANA BEACH, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
30/09/2025
Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-1 63% (26/41) disease control rate (“DCR”) and 37% (15/41) [...]
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements
30/09/2025
Not for dissemination in the United States of America VANCOUVER, British Columbia, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Aja Health and Wellness Inc. ("Aja" or the "Company") (TSXV:Aja) announces that it is getting closer [...]
INVO Fertility to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
29/09/2025
SARASOTA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on expanding access to advanced treatment through the [...]
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
29/09/2025
– Extends cash runway into at least mid-2027 – SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific [...]
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
29/09/2025
Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients in Cohort 9 [...]
Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
29/09/2025
Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fiscal Q2 2027 [...]
Precision Optics Reports Fourth Quarter and Fiscal Year 2025 Financial Results
29/09/2025
Conference Call Scheduled for today, September 29, 2025, at 5:00pm ET Company introduces fiscal year 2026 Revenue and Adjusted EBITDA guidance Company appoints new Chief Operating Officer GARDNER, Mass., Sept. 29, 2025 [...]
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
29/09/2025
PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today [...]
MAIA Biotechnology Announces $2.25 Million Private Placement
29/09/2025
CHICAGO, IL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today [...]
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
29/09/2025
Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunities Upon completion, the royalty management company will manage royalties and [...]

Pages